CClinicalTrials.gg
CompletedNCT00106327Updated Jul 25, 2012

Improving Functioning in Peripheral Arterial Disease

An interventional study of Exercise and Diet in Cardiovascular Diseases and Peripheral Vascular Diseases, sponsored by Northwestern University. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2012-07-25.

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
156
Allocation
Randomized
Sex
All
01

Study summary

The purpose of this study is to compare the effects of nutrition, a supervised treadmill exercise program, and supervised progressive resistance training program on peripheral arterial disease.

Read the detailed description

BACKGROUND:

Previous work demonstrates that functional limitations associated with peripheral arterial disease (PAD) are diverse and include slower walking speed, poorer walking endurance, and impaired balance as compared to persons without PAD. Although treadmill-walking exercise improves treadmill performance in patients with intermittent claudication (IC), treadmill performance does not correlate well with community walking ability in older men and women. In older patient populations without PAD, resistance training improves functioning and walking endurance, but this mode of exercise has not been sufficiently studied in PAD. Furthermore, although 65% to 70% of men and women with PAD are either asymptomatic or have exertional leg symptoms other than IC, no prior studies have assessed the effects of exercise interventions in PAD patients who do not have IC.

DESIGN NARRATIVE:

The randomized, control study will determine whether a 6-month supervised treadmill exercise program and a supervised lower extremity progressive resistance training program, respectively, improve lower extremity functioning compared to a nutrition control group among 150 PAD patients with and without IC. The investigators hypothesize that participants in the treadmill walking exercise program and participants in the progressive resistance training program, respectively, will experience greater improvement in functional outcomes than participants in the nutrition control group. The primary functional outcome measures in descending order of importance are 6-minute walk distance and the summary performance score. The summary performance score is a composite measure of lower extremity functioning (usual walking speed, standing balance, and time required for five repeated chair rises) measured on a 0-12 scale that predicts future risk of nursing home placement, mobility loss, and mortality. The study will also identify mechanisms by which the exercise interventions improve functioning in PAD. Mechanisms to be studied include changes in blood viscosity, calf blood flow, brachial artery endothelial reactivity, and inflammatory cytokine levels. By identifying the optimal exercise program for improving functioning in PAD patients with and without IC, the findings will have substantial clinical and public health implications for millions of patients with PAD.

02

Conditions studied

03

In context

Cardiovascular Diseases

4,902 studies on the registry are indexed under Cardiovascular Diseases; 920 are open to participants now.

This study's enrollment of 156 is above the median of 100 across 2,738 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Northwestern University is the lead sponsor of 1,395 studies on the registry; 198 are open to participants now.

Of its 102 completed or terminated interventional studies of FDA-regulated products, 73 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 150 peripheral arterial disease patients with and without IC

Exclusion criteria

Exclusion Criteria:

  • Below or above-knee amputation
  • Wheelchair confinement
  • Inability to walk on a treadmill or inability to perform progressive resistance training
  • Inability to return to the medical center three times weekly for 6 months
  • Walking impairment due to a cause other than PAD
  • Class II New York Heart Association (NYHA) heart failure or angina (heart failure or angina occurring at rest or with minimal exertion)
  • Planned lower extremity revascularization or any other major surgery within 12 months
  • Any increase in anginal symptoms during the previous 6 months or angina at rest
  • Subjects with silent coronary ischemia, defined as ST segment depression greater than or equal to 1 mm during baseline exercise treadmill test without associated chest discomfort, unless they have had a normal perfusion stress test during the previous 6 months
  • Subjects with left-bundle branch block or significant ST-T wave changes on their baseline ECG who do not have a perfusion stress test demonstrating absence of reversible ischemia within the previous 6 months
  • Lower extremity revascularization, major orthopedic surgery, or other major surgery during the previous 3 months
  • Myocardial infarction or coronary artery bypass grafting during the previous 3 months
  • Major medical illnesses that may interfere with subject's ability to complete the interventions and/or follow-up testing
  • Current foot ulcer
  • ABI greater than 0.95
  • Life expectancy less than 12 months
  • Does not speak English
  • Patient is currently involved in another clinical trial
  • Dementia
  • Poorly controlled blood pressure
  • Current significant exercise, defined as exercising three times weekly for 30 minutes with sufficient exertion to produce a sweat or other exercise that is comparable to the exercise interventions offered in our protocol
  • Treatment for cancer (other than non-melanoma skin cancer) during the past 12 months (including radiation therapy, chemotherapy, or surgery)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
156 participants (actual)

Study arms

  • Experimental
    1

    6-month supervised treadmill exercise program

    Behavioral: Exercise

  • Experimental
    2

    6-month supervised lower extremity progressive resistance training program

    Behavioral: Exercise

  • Active comparator
    3

    Diet/nutrition control group

    Behavioral: Diet

Interventions

  • BehavioralExercise

    6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.

  • BehavioralDiet

    11 nutrition education sessions

06

What researchers measure

Primary outcomes

  1. Six-minute walk distance

    Time frame: Measured at baseline and follow-up study visits

  2. Summary performance score

    Time frame: Measured at baseline and follow-up study visits

07

Study locations

1 site
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611-3008, United States
08

References and documents

Publications

  • McDermott MM, Tian L, Criqui MH, Ferrucci L, Greenland P, Guralnik JM, Kibbe MR, Li L, Sufit R, Zhao L, Polonsky TS. Perceived Versus Objective Change in Walking Ability in Peripheral Artery Disease: Results from 3 Randomized Clinical Trials of Exercise Therapy. J Am Heart Assoc. 2021 Jun 15;10(12):e017609. doi: 10.1161/JAHA.120.017609. Epub 2021 Jun 2. PubMed 34075780 ↗
  • Patel K, Polonsky TS, Kibbe MR, Guralnik JM, Tian L, Ferrucci L, Criqui MH, Sufit R, Leeuwenburgh C, Zhang D, Zhao L, McDermott MM. Clinical characteristics and response to supervised exercise therapy of people with lower extremity peripheral artery disease. J Vasc Surg. 2021 Feb;73(2):608-625. doi: 10.1016/j.jvs.2020.04.498. Epub 2020 May 19. PubMed 32416309 ↗
  • McDermott MM, Kibbe MR, Guralnik JM, Ferrucci L, Criqui MH, Domanchuk K, Tian L, Zhao L, Li L, Patel K, Polonsky TS. Durability of Benefits From Supervised Treadmill Exercise in People With Peripheral Artery Disease. J Am Heart Assoc. 2019 Jan 8;8(1):e009380. doi: 10.1161/JAHA.118.009380. PubMed 30587066 ↗
  • McDermott MM, Ferrucci L, Guralnik JM, Dyer AR, Liu K, Pearce WH, Clark E, Liao Y, Criqui MH. The ankle-brachial index is associated with the magnitude of impaired walking endurance among men and women with peripheral arterial disease. Vasc Med. 2010 Aug;15(4):251-7. doi: 10.1177/1358863X10365181. Epub 2010 May 28. Erratum In: Vasc Med. 2010 Dec;15(6):517. PubMed 20511294 ↗
  • Payvandi L, Dyer A, McPherson D, Ades P, Stein J, Liu K, Ferrucci L, Criqui MH, Guralnik JM, Lloyd-Jones D, Kibbe MR, Liang ST, Kane B, Pearce WH, Verta M, McCarthy WJ, Schneider JR, Shroff A, McDermott MM. Physical activity during daily life and brachial artery flow-mediated dilation in peripheral arterial disease. Vasc Med. 2009 Aug;14(3):193-201. doi: 10.1177/1358863X08101018. PubMed 19651668 ↗
  • McDermott MM, Ades P, Guralnik JM, Dyer A, Ferrucci L, Liu K, Nelson M, Lloyd-Jones D, Van Horn L, Garside D, Kibbe M, Domanchuk K, Stein JH, Liao Y, Tao H, Green D, Pearce WH, Schneider JR, McPherson D, Laing ST, McCarthy WJ, Shroff A, Criqui MH. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA. 2009 Jan 14;301(2):165-74. doi: 10.1001/jama.2008.962. Erratum In: JAMA. 2012 Apr 25;307(16):1694. PubMed 19141764 ↗
  • McDermott MM, Ades PA, Dyer A, Guralnik JM, Kibbe M, Criqui MH. Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg. 2008 Nov;48(5):1231-7, 1237.e1. doi: 10.1016/j.jvs.2008.06.050. Epub 2008 Oct 1. PubMed 18829215 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00106327
Lead sponsor
Northwestern University
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Mary McDermott (Principal Investigator, Northwestern University) — Principal investigator
First posted
Mar 23, 2005
Start date
Sep 2003
Primary completion
Jul 2008
Completion
Mar 2009
Last update
Jul 25, 2012

Study contacts

Mary McDermott, MD
principal investigator · Northwestern University Feinberg School of Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion